Drug Trial Radar · NCT06314685
Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,450
Actual
Start
Dec 10, 2021
Primary completion
Aug 30, 2024
Study completion Aug 30, 2024
Sponsor
- Lead sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 5 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the immunogenicity and safety of Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 months to 5 years old.
Conditions
- Healthy Population
Interventions
Group ACYW135 Meningococcal Polysaccharide Conjugate VaccineBiological
As a experimental vaccine for 6 months to 5 years old.
Group A and C Meningococcal Polysaccharide VaccineBiological
As a control vaccine for ages 6-11 months and 12-23 months.
Group ACYW135 Meningococcal Polysaccharide VaccineBiological
As a control vaccine for ages 2-5 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Antibody positive conversion rateTime frame: 30 day after primary immunization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hunan Center for Disease Control and Prevention
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.